Sort
48,018 grants matching “immunotherapy”
Bioengineering of a New Antibody Drug Delivery Technology
$508,143Ruben J. Boado · Armagen Technologies, Inc. · R44 · FY2012 · MH
Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
$508,105Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2017 · CA
Collaborative Innate-Adaptive Immune Regulation of Tumor Progression
$508,070Matthew F Krummel · University Of California, San Francisco · U01 · FY2013 · CA
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
$507,942Hyung L Kim · Cedars-Sinai Medical Center · R01 · FY2009 · CA
Immunologic Basis of Cow's Milk-Induced Hypersensitivities
$507,899Hugh Sampson · Icahn School Of Medicine At Mount Sinai · U19 · FY2014 · AI
Focal segmental glomerulosclerosis: Treatment
$507,890Jeffrey Burnett Kopp · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK
CAREER: An Immunoengineering Approach to Create Purely Synthetic Microenvironments Enabling Generation of Antigen-Specific Effector B cells
$507,777Kyung-Ho Roh · University Of Alabama In Huntsville · · FY2020 · ENG
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$507,690Arthur Andrew Hurwitz · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) - DCC
$507,689Scott S Emerson · University Of Washington · U01 · FY2016 · HL
Mechanisms by which effector T cells modulate endogenous remyelination
$507,648Peter A Calabresi · Johns Hopkins University · R01 · FY2021 · NS
Overcoming obesity-associated immunotherapy resistance in renal cancer
$507,581Lyse A Norian · University Of Alabama At Birmingham · R01 · FY2024 · CA
Vanderbilt Network Lead Academic Participating Site for the NCTN
$507,576Jordan D Berlin · Vanderbilt University Medical Center · UG1 · FY2022 · CA
Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma
$507,574David Zaharoff · North Carolina State University Raleigh · U01 · FY2024 · CA
Project 2: Targeting differentiation-linked redox sensitivity in melanoma
$507,564Thomas G Graeber · University Of California Los Angeles · P01 · FY2022 · CA
Project 2: Targeting differentiation-linked redox sensitivity in melanoma
$507,564Thomas G Graeber · University Of California Los Angeles · P01 · FY2023 · CA
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma
$507,564Roger S Lo · University Of California Los Angeles · P01 · FY2022 · CA
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma
$507,563Roger S Lo · University Of California Los Angeles · P01 · FY2023 · CA
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
$507,562Antoni Ribas · University Of California Los Angeles · P01 · FY2022 · CA
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
$507,562Antoni Ribas · University Of California Los Angeles · P01 · FY2023 · CA
Improving the translational value of head and neck cancer patient-in-mouse models
$507,439Randall J Kimple · University Of Wisconsin-Madison · R37 · FY2023 · CA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$507,430Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Multi-organ culture and pumping systems for ex vivo models of immunity in hybrid tissue-chips
$507,339Rebecca R Pompano · University Of Virginia · R01 · FY2023 · AI
Nanovaccine platforms to combat pancreatic cancer
$507,337Balaji Narasimhan · Iowa State University · U01 · FY2021 · CA
Function of Wdfy4 in cross-presentation and immunity
$507,323Kenneth M. Murphy · Washington University · R01 · FY2022 · AI
Fluidic Protein Vesicles for High-Density Signal Presentation in Immunomodulatory Biomaterials
$507,298Yeongseon Jang · University Of Florida · · FY2026 · MPS